The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Mavyret is an antiviral drug prescribed to treat hepatitis C (HCV). It comes as oral tablets and pellets. Mavyret works by stopping HCV from multiplying, which can cure this condition. Mavyret is ...

XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus ...

Mavyret was initially approved in 2017 for newly diagnosed adult Hepatitis C patients. AbbVie Inc. (NYSE:ABBV) is an international biopharmaceutical firm dedicated to creating and providing advanced ...

The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals, Inc.

FDA approved a label expansion for Mavyret for the treatment of acute hepatitis C virus, according to a press release from the manufacturer, AbbVie.

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus infections in adults and children aged three years and older, without cirrhosis or ...

MAVYRET and other medicines may affect each other. This can cause you to have too much or not enough MAVYRET or other medicines in your body.

MAVYRET is now approved for both acute and chronic HCV infection in adults and pediatric patients three years and older without cirrhosis or with compensated cirrhosis. While the company maintains ...